LBPH Fundamental Analysis - Longboard Pharmaceuticals Inc

Fundamental Rating

LBPH gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 196 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for LBPH as it has an excellent financial health rating, but there are worries on the profitability. LBPH is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year LBPH has reported negative net income.

LBPH had a negative operating cash flow in the past year.

1.2 Ratios

LBPH has a Return On Assets (-25.70%) which is comparable to the rest of the industry.

With a decent Return On Equity value of -27.74%, LBPH is doing good in the industry, outperforming 67.71% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-25.7%
ROE	-27.74%
ROIC	N/A

ROA(3y)-65.03%

ROA(5y)N/A

ROE(3y)-77.12%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for LBPH so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, LBPH has more shares outstanding

LBPH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 63.60 indicates that LBPH is not in any danger for bankruptcy at the moment.

LBPH has a better Altman-Z score (63.60) than 96.88% of its industry peers.

There is no outstanding debt for LBPH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	63.6

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

LBPH has a Current Ratio of 15.97. This indicates that LBPH is financially healthy and has no problem in meeting its short term obligations.

LBPH's Current ratio of 15.97 is amongst the best of the industry. LBPH outperforms 88.54% of its industry peers.

LBPH has a Quick Ratio of 15.97. This indicates that LBPH is financially healthy and has no problem in meeting its short term obligations.

LBPH has a Quick ratio of 15.97. This is amongst the best in the industry. LBPH outperforms 88.54% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	15.97
Quick Ratio	15.97

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

LBPH shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 7.85%.

EPS 1Y (TTM)7.85%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-14.55%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

LBPH is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 2.83% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y4.61%

EPS Next 2Y-10.02%

EPS Next 3Y-10.5%

EPS Next 5Y2.83%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

LBPH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LBPH. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as LBPH's earnings are expected to decrease with -10.50% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-10.02%

EPS Next 3Y-10.5%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for LBPH!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

Longboard Pharmaceuticals Inc

NASDAQ:LBPH (11/29/2024, 7:46:54 PM)

After market: 60.01 +0.03 (+0.05%)

59.98

+0.02 (+0.03%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)11-07 2024-11-07/amc

Earnings (Next)N/A N/A

Inst Owners101.95%

Inst Owner Change0%

Ins Owners0.04%

Ins Owner Change0%

Market Cap2.34B

Analysts75.38

Price Target65.96 (9.97%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)0

Avg EPS beat(2)-15.68%

Min EPS beat(2)-24.62%

Max EPS beat(2)-6.75%

EPS beat(4)1

Avg EPS beat(4)-4.45%

Min EPS beat(4)-24.62%

Max EPS beat(4)15.33%

EPS beat(8)4

Avg EPS beat(8)1.23%

EPS beat(12)5

Avg EPS beat(12)-2.26%

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)2.18%

EPS NQ rev (1m)-1.15%

EPS NQ rev (3m)-24.01%

EPS NY rev (1m)-1.17%

EPS NY rev (3m)-7.89%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	8.51
P/tB	8.51
EV/EBITDA	N/A

EPS(TTM)-2.23

EYN/A

EPS(NY)-2.88

Fwd EYN/A

FCF(TTM)-1.69

FCFYN/A

OCF(TTM)-1.69

OCFYN/A

SpS0

BVpS7.05

TBVpS7.05

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-25.7%
ROE	-27.74%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-65.03%

ROA(5y)N/A

ROE(3y)-77.12%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score6

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	15.97
Quick Ratio	15.97
Altman-Z	63.6

F-Score6

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)7.85%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-14.55%

EPS Next Y4.61%

EPS Next 2Y-10.02%

EPS Next 3Y-10.5%

EPS Next 5Y2.83%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-65.28%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-67.64%

EBIT Next 3Y-40.09%

EBIT Next 5Y22.5%

FCF growth 1Y-93.46%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-93.52%

OCF growth 3YN/A

OCF growth 5YN/A

Longboard Pharmaceuticals Inc (LBPH) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens